Cart
sales@molnova.com
SD-70
CAS No. 332173-89-4
SD-70( SD70 )
Catalog No. M14117 CAS No. 332173-89-4
A small molecule tumor translocation inhibitor that inhibits the prostate cancer cell transcriptional program.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 100MG | Get Quote | Get Quote |
|
| 200MG | Get Quote | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameSD-70
-
NoteResearch use only, not for human use.
-
Brief DescriptionA small molecule tumor translocation inhibitor that inhibits the prostate cancer cell transcriptional program.
-
DescriptionA small molecule tumor translocation inhibitor that inhibits the prostate cancer cell transcriptional program, in part by inhibition of the demethylase KDM4C (IC50=30 uM); represses AR transcriptional program, increases H3K9me2 levels in 293T cells; inhibits tumor growth in CWR22Rv1 prostate cancer xenograft mice model.
-
In Vitro——
-
In Vivo——
-
SynonymsSD70
-
PathwayChromatin/Epigenetic
-
TargetHistone Demethylase
-
RecptorHistone Demethylase
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number332173-89-4
-
Formula Weight310.353
-
Molecular FormulaC18H18N2O3
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES——
-
Chemical NameN-(furan-2-yl(8-hydroxyquinolin-7-yl)methyl)isobutyramide
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Jin C, et al. Proc Natl Acad Sci U S A. 2014 Jun 24;111(25):9235-40.
molnova catalog
related products
-
GSK-LSD1 dihydrochlo...
GSK-LSD1 2HCl is a specificity irreversible LSD1 inhibitor (IC50: 16 nM). The selectivity of GSK-LSD1 for LSD1 is >1000 fold over other closely related FAD utilizing enzymes (i.e. MAO-A, LSD2, MAO-B).
-
GSK J5
GSK J5 is an inhibitor of schistosomes and helminths and is often used as a trematode insecticide.GSK J5 promotes schistosome mortality in a dose- and time-dependent manner.
-
KDM5-IN-48
A potent, selective and orally bioavailable KDM5 inhibitor with biochemical IC50 of 15.1, 4.7 and 65.5 nM for KDM5A, KDM5B and KDM5C, respectively.
